Cel­gene antes up $55M, grabs op­tion to buy the au­toim­mune up­start Anokion

Cel­gene’s glo­be­trot­ting busi­ness de­vel­op­ment team has fo­cused on au­toim­mune dis­eases for its lat­est col­lab­o­ra­tion/op­tion-to-buy biotech deal.

The fo­cus this time: Anokion, a spin­out of the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER